Cytarabine Liposomal / Daunorubicin Liposomal Dosage
Medically reviewed by Drugs.com. Last updated on Sep 15, 2017.
Applies to the following strengths: 100 mg-44 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Acute Myeloid Leukemia
-First Induction (Cycle 1): (Cytarabine 100 mg/m2 and daunorubicin 44 mg/m2) liposome IV over 90 minutes on days 1, 3, and 5
-Second Induction (for patients who do not achieve remission with first cycle): (Cytarabine 100 mg/m2 and daunorubicin 44 mg/m2) liposome IV over 90 minutes on days 1, and 3 administered 2 to 5 weeks after the first induction cycle (if no unacceptable toxicity with first induction)
-Consolidation: (Cytarabine 65 mg/m2 and daunorubicin 29 mg/m2) liposome IV over 90 minutes on days 1 and 3; administer the first consolidation cycle 5 to 8 weeks after the start of the last induction; administer the second consolidation cycle 5 to 8 weeks after the start of the first consolidation cycle in patients who do not show disease progression or unacceptable toxicity
-Prior to initiating induction, assess cardiac function and obtain liver and renal function studies.
-For patients who do not achieve remission with the first induction cycle, a second induction cycle may be administered 2 to 5 weeks after the first if there was no unacceptable toxicity.
Use: For newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Renal Dose Adjustments
-Mild renal impairment (CrCl 60 to 89 mL/min): No adjustment recommended.
-Moderate renal impairment (CrCl 30 to 59 mL/min): No adjustment recommended.
-Severe renal impairment (CrCl 15 to 29 mL/min) or end-stage renal disease: Data not available
Liver Dose Adjustments
-Bilirubin less than or equal to 3 mg/dL: No adjustment recommended.
-Bilirubin greater than 3 mg/dL: Data not available
-If a dose is missed, administer as soon as possible and adjust the dosing schedule, maintaining therapy interval.
For hypersensitivity reactions of any grade/severity, interrupt the infusion immediately and manage symptoms. Reduce the rate of infusion or discontinue therapy for:
-Mild symptoms: Once symptoms resolve, reinitiate infusion at half the prior rate. Consider premedication with antihistamines and/or corticosteroids for subsequent doses.
-Moderate symptoms: Do not reinitiate infusion. For subsequent doses, premedicate with antihistamines and/or corticosteroids prior to initiating infusion at same rate.
-Severe/life-threatening symptoms: Permanently discontinue therapy, treat symptoms, and monitor patient until symptoms resolve.
-Discontinue therapy in patients who exhibit impaired cardiac function unless benefit outweighs risk.
US BOXED WARNINGS:
-This combination drug has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-For IV use only.
-Do not mix or administer this drug combination with other drugs.
-Administer by continuous IV infusion over 90 minutes via an infusion pump through a central venous catheter or a peripherally inserted central catheter. Do not use an in-line filter.
-Flush the line after administration with 0.9% sodium chloride injection or 5% dextrose injection.
-Store unreconstituted vials in a refrigerator at 2C to 8C (36F to 46F) in an upright position.
-The vial should be stored in its original carton to protect from light.
-The manufacturer product information should be consulted.
-This drug combination is cytotoxic. Follow special handling and disposal procedures.
-This drug combination is supplied as a single-dose vial and does not contain any preservatives. Do not save any unused portions for later administration.
-This drug can cause fetal harm when administered during pregnancy. Females of reproductive potential should use effective contraception during therapy and for at least 6 months following the last dose.
-Do not breastfeed during therapy and for at least 2 weeks after the last dose.
-Males of reproductive potential should be aware that this drug combination may cause temporary or permanent infertility.
-This drug combination may cause fatal bleeding.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about cytarabine liposomal/daunorubicin liposomal
- Cytarabine and daunorubicin liposomal
- Daunorubicin and Cytarabine (Liposomal)
- Daunorubicin and cytarabine liposome Intravenous (Advanced Reading)
Other brands: Vyxeos